• Consensus Rating: Hold
  • Consensus Price Target: $145.57
  • Forecasted Upside: 54.91%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.4 (0.43%)

This chart shows the closing price for BNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioNTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

Analyst Price Target is $145.57
▲ +54.91% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $145.57, with a high forecast of $260.00 and a low forecast of $99.00. The average price target represents a 54.91% upside from the last price of $93.97.

This chart shows the closing price for BNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in BioNTech. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2024BMO Capital MarketsInitiated CoverageOutperform$127.00Low
2/20/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$168.00 ➝ $171.00Low
1/23/2024HC WainwrightLower TargetBuy ➝ Buy$133.00 ➝ $107.00Low
1/5/2024OppenheimerInitiated CoverageMarket PerformLow
12/1/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$106.00 ➝ $99.00Low
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$133.00Low
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$180.00 ➝ $133.00Low
11/8/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $111.00Low
10/17/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$116.00 ➝ $110.00Low
10/16/2023HSBCDowngradeBuy ➝ Hold$124.00 ➝ $111.00Low
8/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$180.00Low
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$181.00 ➝ $180.00N/A
8/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$119.00 ➝ $116.00Low
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$119.00Low
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$119.00Low
7/14/2023HSBCInitiated CoverageBuy$124.00Low
6/1/2023HC WainwrightLower Target$198.00 ➝ $181.00Low
5/23/2023HC WainwrightLower Target$210.00 ➝ $198.00Low
5/18/2023Deutsche Bank AktiengesellschaftLower Target$135.00 ➝ $120.00Low
5/17/2023Redburn PartnersUpgradeNeutral ➝ Buy$165.00 ➝ $170.00Low
4/10/2023JPMorgan Chase & Co.Lower TargetNeutral$142.00 ➝ $128.00Low
3/31/2023UBS GroupLower TargetNeutral$168.00 ➝ $153.00N/A
3/30/2023HC WainwrightReiterated RatingBuy$210.00Low
3/28/2023Canaccord Genuity GroupBoost TargetBuy$191.00 ➝ $203.00Low
3/28/2023TD CowenLower TargetMarket Perform$145.00 ➝ $130.00Low
3/28/2023The Goldman Sachs GroupSet TargetNeutral$156.00 ➝ $140.00Low
3/28/2023Berenberg BankSet Target$260.00Low
3/28/2023Morgan StanleyLower TargetEqual Weight$216.00 ➝ $150.00Low
3/28/2023Jefferies Financial GroupSet Target$145.00Low
3/27/2023Bank of AmericaLower TargetBuy$239.00 ➝ $194.00Low
3/23/2023HC WainwrightLower TargetBuy$272.00 ➝ $210.00Low
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$148.00 ➝ $142.00Low
2/1/2023UBS GroupSet Target$168.00Low
1/31/2023The Goldman Sachs GroupLower TargetNeutral$177.00 ➝ $156.00Low
1/30/2023Berenberg BankSet Target$300.00Low
1/24/2023Morgan StanleyBoost TargetEqual Weight$203.00 ➝ $216.00Low
1/16/2023The Goldman Sachs GroupSet Target$177.00Low
1/11/2023JPMorgan Chase & Co.Set Target$148.00Low
12/15/2022Bank of AmericaUpgradeNeutral ➝ Buy$239.00Low
11/21/2022JPMorgan Chase & Co.Set Target$148.00Low
11/15/2022UBS GroupSet Target$168.00Low
11/8/2022Berenberg BankSet Target$312.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$194.00 ➝ $203.00Low
11/8/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$200.00 ➝ $191.00Low
11/8/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $177.00Low
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$183.00 ➝ $132.00Low
10/21/2022Berenberg BankSet Target$312.00Low
9/27/2022Berenberg BankSet Target$312.00Low
9/8/2022Deutsche Bank AktiengesellschaftSet Target$180.00Low
9/8/2022Berenberg BankSet Target$312.00Low
8/17/2022CowenInitiated CoverageMarket Perform$177.00Low
8/17/2022CowenInitiated CoverageMarket PerformLow
8/10/2022HC WainwrightLower TargetBuy$283.00 ➝ $272.00Low
8/9/2022The Goldman Sachs GroupSet Target$200.00Low
8/9/2022Berenberg BankSet Target$312.00Low
8/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$192.00 ➝ $200.00Low
7/29/2022SVB LeerinkBoost TargetOutperform$223.00 ➝ $224.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$195.00 ➝ $194.00Low
7/13/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$253.00 ➝ $223.00Low
7/11/2022HC WainwrightLower TargetBuy$298.00 ➝ $283.00N/A
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$192.00N/A
7/1/2022Deutsche Bank AktiengesellschaftSet Target$180.00Low
6/30/2022The Goldman Sachs GroupSet Target$209.00Low
6/30/2022UBS GroupSet Target$168.00Low
6/15/2022The Goldman Sachs GroupSet Target$206.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$255.00 ➝ $206.00Low
5/11/2022The Goldman Sachs GroupSet Target$255.00Medium
5/10/2022JPMorgan Chase & Co.Set Target$183.00High
5/9/2022Jefferies Financial GroupSet Target$230.00Low
4/12/2022HC WainwrightLower TargetBuy$339.00 ➝ $298.00Medium
4/12/2022Morgan StanleyLower TargetEqual Weight$217.00 ➝ $197.00Low
4/11/2022Berenberg BankReiterated RatingBuy$350.00Low
4/5/2022Canaccord Genuity GroupLower TargetBuy$450.00 ➝ $300.00Medium
4/5/2022UBS GroupLower TargetBuy ➝ Buy$450.00 ➝ $300.00Low
4/5/2022Berenberg BankSet Target$400.00N/A
4/1/2022The Goldman Sachs GroupSet Target$255.00High
4/1/2022Deutsche Bank AktiengesellschaftSet Target$200.00High
3/31/2022JPMorgan Chase & Co.Set Target$183.00Low
3/30/2022Jefferies Financial GroupSet Target$230.00High
3/18/2022Jefferies Financial GroupSet Target$230.00Medium
2/23/2022HC WainwrightLower TargetBuy$366.00 ➝ $339.00High
2/14/2022HC WainwrightReiterated RatingBuy$366.00High
2/1/2022Morgan StanleyLower TargetEqual Weight$284.00 ➝ $217.00Medium
2/1/2022Redburn PartnersUpgradeSell ➝ NeutralLow
1/19/2022HC WainwrightReiterated RatingBuy$366.00High
1/18/2022Morgan StanleyLower TargetEqual Weight$294.00 ➝ $284.00High
1/12/2022The Goldman Sachs GroupSet Target$299.00Low
1/5/2022Berenberg BankSet Target$400.00Low
1/4/2022HC WainwrightReiterated RatingBuy$366.00Medium
12/22/2021UBS GroupUpgradeNeutral ➝ BuyHigh
12/21/2021HC WainwrightBoost TargetBuy$360.00 ➝ $366.00High
12/16/2021Morgan StanleyInitiated CoverageEqual Weight$294.00Medium
12/9/2021Deutsche Bank AktiengesellschaftSet Target$225.00Medium
12/8/2021Berenberg BankSet Target$400.00Low
12/8/2021Jefferies Financial GroupSet Target$230.00Low
12/6/2021Bank of AmericaBoost TargetNeutral ➝ Neutral$341.00 ➝ $349.00High
11/29/2021Berenberg BankSet Target$400.00Low
11/22/2021Jefferies Financial GroupSet Target$230.00High
11/10/2021HC WainwrightUpgradeNeutral ➝ Buy$242.00 ➝ $360.00Medium
11/10/2021JPMorgan Chase & Co.Set Target$180.00Low
11/9/2021Jefferies Financial GroupSet Target$230.00High
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00High
10/7/2021Jefferies Financial GroupSet Target$230.00High
10/6/2021Jefferies Financial GroupInitiated CoverageHold$230.00High
10/5/2021HC WainwrightReiterated RatingHold$330.00Low
10/5/2021Berenberg BankSet Target$400.00Low
10/5/2021SVB LeerinkLower TargetMarket Perform$293.00 ➝ $268.00Low
10/5/2021Bryan, Garnier & CoSet Target$359.00Low
9/29/2021HC WainwrightReiterated RatingHold$330.00Low
9/29/2021The Goldman Sachs GroupSet Target$433.00Low
9/24/2021Bryan, Garnier & CoSet Target$451.00High
9/23/2021UBS GroupSet Target$300.00Low
9/23/2021The Goldman Sachs GroupSet Target$433.00Low
9/21/2021HC WainwrightReiterated RatingHold$330.00Low
8/31/2021HC WainwrightReiterated RatingHold$330.00Medium
8/27/2021UBS GroupBoost TargetNeutral$111.00 ➝ $300.00Medium
8/13/2021SVB LeerinkBoost TargetMarket Perform$159.00 ➝ $293.00Low
8/11/2021HC WainwrightBoost TargetNeutral$194.00 ➝ $330.00High
8/11/2021Bryan, Garnier & CoUpgradeNeutral ➝ BuyHigh
8/8/2021The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
7/22/2021SVB LeerinkReiterated RatingHoldLow
7/20/2021HC WainwrightReiterated RatingHold$194.00High
7/19/2021Wolfe ResearchInitiated CoverageOutperform$248.00High
7/14/2021HC WainwrightReiterated RatingHold$194.00Low
6/23/2021SVB LeerinkReiterated RatingHoldMedium
6/16/2021Redburn PartnersReiterated RatingNeutral ➝ Sell$146.00High
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$173.00Low
5/17/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$135.00 ➝ $206.00N/A
5/11/2021SVB LeerinkBoost TargetPositive ➝ Market Perform$118.00 ➝ $159.00Low
5/11/2021Bryan, Garnier & CoDowngradeBuy ➝ Neutral$135.00 ➝ $206.00Low
4/13/2021SVB LeerinkBoost TargetMarket Perform$110.00 ➝ $118.00High
4/6/2021SVB LeerinkBoost TargetMarket Perform$106.00 ➝ $110.00Low
4/6/2021Berenberg BankSet TargetBuy$130.00Medium
4/6/2021JPMorgan Chase & Co.Set TargetNeutral$104.00Medium
3/31/2021JPMorgan Chase & Co.Reiterated RatingNeutral$104.00Low
3/31/2021Berenberg BankReiterated RatingBuy$130.00Medium
2/4/2021SVB LeerinkBoost TargetMarket Perform$97.00 ➝ $106.00Low
1/11/2021Berenberg BankSet TargetBuy$126.00High
12/15/2020SVB LeerinkBoost TargetMarket Perform$91.00 ➝ $97.00Low
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$123.00 ➝ $126.00High
11/24/2020SVB LeerinkBoost TargetMarket Perform$90.00 ➝ $91.00Low
11/16/2020Berenberg BankReiterated RatingBuy$126.00Medium
11/10/2020JPMorgan Chase & Co.Set TargetNeutral$90.00Medium
11/10/2020SVB LeerinkBoost TargetMarket Perform$64.00 ➝ $90.00High
10/29/2020CommerzbankInitiated CoverageBuy$119.00High
10/14/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$62.00 ➝ $69.00High
9/22/2020Berenberg BankReiterated RatingBuy$98.00Medium
8/6/2020SVB LeerinkBoost TargetMarket Perform$42.00 ➝ $69.00High
8/3/2020Berenberg BankInitiated CoverageBuy$98.00Medium
7/27/2020HC WainwrightReiterated RatingHoldLow
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/20/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/14/2020HC WainwrightReiterated RatingHoldHigh
7/2/2020Bryan, Garnier & CoBoost Target$50.00 ➝ $62.00High
7/2/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$37.00 ➝ $42.00High
6/30/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
6/25/2020HC WainwrightLower TargetBuy$69.00 ➝ $63.00High
5/19/2020HC WainwrightUpgradeNeutral ➝ Buy$48.00 ➝ $69.00High
4/28/2020Bank of AmericaDowngradeBuy ➝ Neutral$51.00Medium
4/13/2020HC WainwrightReiterated RatingNeutral$30.00 ➝ $48.00High
3/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $33.00High
3/17/2020HC WainwrightReiterated RatingHold$30.00High
3/9/2020HC WainwrightInitiated CoverageNeutral$30.00High
1/22/2020UBS GroupDowngradeBuy ➝ Neutral$21.00 ➝ $35.00Medium
11/5/2019Wolfe ResearchInitiated CoverageOutperform$21.00 ➝ $21.00Low
11/4/2019SVB LeerinkInitiated CoverageOutperformHigh
11/4/2019Berenberg BankInitiated CoverageBuy$25.00High
11/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
11/4/2019JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
11/4/2019UBS GroupInitiated CoverageBuy$21.00High
(Data available from 2/24/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 15 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
  • 18 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
  • 21 very positive mentions
  • 40 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 21 very positive mentions
  • 40 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

BioNTech logo
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Read More

Today's Range

Now: $93.97
Low: $92.51
High: $94.88

50 Day Range

MA: $99.75
Low: $90.58
High: $112.35

52 Week Range

Now: $93.97
Low: $88.00
High: $136.91


493,335 shs

Average Volume

481,632 shs

Market Capitalization

$22.34 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: Bank of America Co., Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Redburn Partners, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, and UBS Group AG.
View the latest analyst ratings for BNTX.

What is the current price target for BioNTech?

14 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $145.57, suggesting a possible upside of 54.9%. Berenberg Bank has the highest price target set, predicting BNTX will reach $260.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $99.00 for BioNTech in the next year.
View the latest price targets for BNTX.

What is the current consensus analyst rating for BioNTech?

BioNTech currently has 1 sell rating, 6 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BNTX, but not buy more shares or sell existing shares.
View the latest ratings for BNTX.

What other companies compete with BioNTech?

Other companies that are similar to BioNTech include argenx, Neurocrine Biosciences, Biogen, Repligen and Bio-Techne. Learn More about companies similar to BioNTech.

How do I contact BioNTech's investor relations team?

BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected]. The official website for BioNTech is www.biontech.de. Learn More about contacing BioNTech investor relations.